+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Labcorp Drug Development - Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 30 Pages
  • June 2025
  • GlobalData
  • ID: 4050671
Labcorp Drug Development - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - The analyst’s summarization of the company’s business strategy.
  • SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

Labcorp Drug Development Inc (Labcorp), formerly Covance Inc, is a contract research company that offers drug development and manufacturing services. Its services include research, lead optimization, analysis services, safety assessment and drug safety testing, consulting and partnering, informatics, clinical testing, clinical development, commercialization, and manufacturing support, among others. It offers solutions in various therapeutic areas such as cardiovascular; diabetes, endocrinology and nephrology; immuno-oncology; infectious diseases; inflammation; neuroscience; non-alcoholic steatohepatitis; oncology; rare disease and orphan drugs; and pediatrics. Labcorp also offers laboratory testing services for agrochemical and chemical industries. It operates in the US, Europe, Latin America, Africa, and Asia-Pacific. The company operates as a subsidiary of Laboratory Corp of America Holdings. Labcorp is headquartered in Burlington, North Carolina, the US.

Labcorp Drug Development Key Recent Developments

  • Sep 18, 2024: Labcorp Expands Molecular Bioanalytical Laboratory in Greenfield, Indiana
  • Jun 03, 2024: Labcorp Announces New Strategic Service Offerings within Precision Oncology Portfolio

Reasons to Buy

  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with the analyst’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.

Table of Contents

Section 1 - About the Company
  • Labcorp Drug Development - Key Facts
  • Labcorp Drug Development - Key Employees
  • Labcorp Drug Development - Key Employee Biographies
  • Labcorp Drug Development - Major Products and Services
  • Labcorp Drug Development - History
  • Labcorp Drug Development - Company Statement
  • Labcorp Drug Development - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Labcorp Drug Development - Business Description
  • Labcorp Drug Development - SWOT Analysis
  • SWOT Analysis - Overview
  • Labcorp Drug Development - Strengths
  • Labcorp Drug Development - Weaknesses
  • Labcorp Drug Development - Opportunities
  • Labcorp Drug Development - Threats
  • Labcorp Drug Development - Key Competitors
Section 3 - Company’s Lifesciences Financial Deals and Alliances
  • Labcorp Drug Development, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
  • Labcorp Drug Development, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
  • Labcorp Drug Development, Recent Deals Summary
Section 4 - Company’s Recent Developments
  • Sep 18, 2024: Labcorp Expands Molecular Bioanalytical Laboratory in Greenfield, Indiana
  • Jun 03, 2024: Labcorp Announces New Strategic Service Offerings within Precision Oncology Portfolio
Section 5 - Appendix
  • Methodology
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Labcorp Drug Development, Key Facts
  • Labcorp Drug Development, Key Employees
  • Labcorp Drug Development, Key Employee Biographies
  • Labcorp Drug Development, Major Products and Services
  • Labcorp Drug Development, History
  • Labcorp Drug Development, Subsidiaries
  • Labcorp Drug Development, Key Competitors
  • Labcorp Drug Development, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
  • Labcorp Drug Development, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
  • Labcorp Drug Development, Recent Deals Summary
List of Figures
  • Labcorp Drug Development, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
  • Labcorp Drug Development, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • ICON Plc
  • ClinOne Inc
  • Parexel International Corp
  • IQVIA Holdings Inc
  • IMA Clinical Research LLC
  • Genesis Biotechnology Group LLC
  • Frontage Holdings Corp
  • PRA International LLC